Applied Molecular Transport 

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its lead product candidate is AMT-101, an oral gastrointestinal (GI) selective interleukin 10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The company, through its technology platform designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and RNA therapeutics. In addition, it engages in the development of AMT-126, a GI-selective oral fusion of rhIL-22 for diseases related to intestinal epithelium barrier function defects. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.